Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,371,599 papers from all fields of science
Search
Sign In
Create Free Account
NSC-655649
Known as:
NSC 655649
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
becatecarin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells
R. Robey
,
Tomasz Obrzut
,
+6 authors
S. Bates
Cancer Chemotherapy and Pharmacology
2009
Corpus ID: 13763666
PurposeABCG2 overexpression has been linked to resistance to topoisomerase inhibitors, leading us to examine the potential…
Expand
2005
2005
Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors
A. Ricart
,
L. Hammond
,
+8 authors
E. Rowinsky
Clinical Cancer Research
2005
Corpus ID: 43589179
Purpose: To evaluate the feasibility of administering NSC 655649, a water-soluble rebeccamycin analogue that inhibits both…
Expand
2003
2003
A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer
M. Hussain
,
U. Vaishampayan
,
+4 authors
L. Flaherty
Investigational new drugs
2003
Corpus ID: 11556614
Objective: Rebeccamycin analog (NSC-655649) is an antibiotic with antitumor properties demonstrated in preclinical and phase I…
Expand
2003
2003
A Phase II Study of Rebeccamycin Analog NSC 655649 in Patients with Metastatic Colorectal Cancer
S. Goel
,
S. Wadler
,
+6 authors
S. Mani
Investigational new drugs
2003
Corpus ID: 21841657
The analog, rebeccamycin tartrate salt (NSC 655649, Cancer Therapy Evaluation Program, National Cancer Institute) has broad…
Expand
2002
2002
Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats.
J. Merchant
,
K. Tutsch
,
+8 authors
G. Wilding
Clinical Cancer Research
2002
Corpus ID: 18583397
PURPOSE NSC 655649 was given in both single- and multiple-dose formats, to characterize maximum tolerated dose (MTD), toxicity…
Expand
2001
2001
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
A. Tolcher
,
S. G. Eckhardt
,
+10 authors
E. Rowinsky
Journal of Clinical Oncology
2001
Corpus ID: 3123929
PURPOSE To assess the feasibility of administering NSC 655649, a water-soluble, rebeccamycin analog with topoisomerase inhibitory…
Expand
2001
2001
Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days.
A. Dowlati
,
Charles L. Hoppel
,
+7 authors
S. Remick
Journal of Clinical Oncology
2001
Corpus ID: 28358097
PURPOSE Rebeccamycin analog (NSC 655649) is active against a variety of both solid and nonsolid tumor cell lines. We performed a…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE